RxDoctor Payments Data

William Schafer, MD

Cardiovascular Disease · Toledo, OHNPI 1932107174

Payments from drug & device makers

$3,261in general payments, 2019–2025

Across 178 payments — averaging $18.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$786
  • Kowa Pharmaceuticals America, Inc.$466
  • AstraZeneca$310
  • Amarin Pharma, Inc.$233
  • E.r. Squibb & Sons, L.L.C.$213
  • Amgen$210
  • plus $1K from 13 others

What the payments were for

  • Food & beverage$3,261100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,261 in reported general payments places this provider in the 60th percentile of 827 cardiovascular disease providers in Ohio.

See all cardiovascular disease providers in Ohio

Medicare billing

Part B allowed, 2024
$75,183
Medicare patients
144
Services billed
901

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban177$211,146
XareltoRivaroxaban112$141,395
EntrestoSacubitril/Valsartan52$68,771
JardianceEmpagliflozin15$26,918
FarxigaDapagliflozin Propanediol20$25,662
VascepaIcosapent Ethyl28$23,100
Repatha SureclickEvolocumab22$13,019
Rosuvastatin Calcium432$7,047
Ezetimibe200$6,105
Nebivolol Hcl101$5,945
Telmisartan127$4,763
Bisoprolol Fumarate114$4,607
Metoprolol Succinate225$3,882
Eplerenone30$3,286
Ranolazine ErRanolazine34$3,199

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$166$211,146177 claims
Johnson & JohnsonXarelto$786$141,395112 claims
NovartisEntresto$25$68,77152 claims
Boehringer IngelheimJardiance$134$26,91815 claims
AstraZenecaFarxiga$310$25,66220 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 827 cardiovascular disease providers in Ohio.

Other cardiovascular disease in Toledo

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →